SCHEMBL3928072

SCHEMBL3928072

Nc1ccc(S(=O)(=O)c2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.55
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
MAOB P27338 2/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 1/20 0.45
MAOA P21397 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LTA4H P09960 1/20 0.44
MAPK14 Q16539 1/20 0.44
HTR6 P50406 4/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3920678 0.80 CYP19A1 (0.63) CYP19A1CYP11B1CYP11B2MAPTALDH1A1
SCHEMBL8866361 0.79 HTR6 (0.65) GAAMAPTHTR6KDM4EALDH1A1
SCHEMBL10342827 0.77 MAOA (0.46) GAAMAPTMAOARAB9ASMN1; SMN2
SCHEMBL5659691 0.76 MAOB (0.58) CYP19A1CYP11B1CYP11B2MAOBGAA
SCHEMBL9360749 0.75 CYP19A1 (0.53) CYP19A1CYP11B1CYP11B2MAOBGAA
Hydrochloric Acid SCHEMBL11596441 0.75 GAA (0.56) CYP19A1CYP11B1CYP11B2MAOBGAA
SCHEMBL8298067 0.75 MAOB (0.56) CYP19A1CYP11B1CYP11B2MAOBGAA
SCHEMBL19404699 0.75 ALOX5AP (0.61) CYP19A1CYP11B1CYP11B2MAOBGAA
SCHEMBL9713926 0.74 ALDH1A1 (0.50) GAAHTR6KDM4EALDH1A1PKM
SCHEMBL7752409 0.74 CA12 (0.60) MAOBGAAMAPTMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC CYP19A1 1354/4885CYP11B1 1623/4885CYP11B2 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.